Ascendis Pharma A/S - Ordinary Share (NQ:ASND)

220.93 -8.45 (-3.68%)

Streaming Delayed Price Updated: 4:00 PM EDT, May 1, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Ascendis Pharma A/S - Ordinary Share

< Previous 1 2 3 4 5 6 7 8 9 Next >

Can BioMarin Stock Live Up to Wall Street’s High Expectations?

November 22, 2024

BioMarin has greatly improved the fundamentals of its business, but continues losing value. Is the tide ready to turn, or is more of the same on the horizon?

Via MarketBeat

(ASND) - Analyzing Ascendis Pharma's Short Interest ↗

November 14, 2024

Via Benzinga

A Glimpse of Ascendis Pharma's Earnings Potential ↗

November 13, 2024

Via Benzinga

Novo Nordisk Q3 Preview: Will $285 Million Weight Loss Bet Offset Bearish Charts? ↗

November 05, 2024

Novo Nordisk is expected to report third-quarter earnings on Wednesday. Stock up 8.55% in a year, 7.45% year-to-date.

Via Benzinga

Wegovy Manufacturer Inks Multi-Million Deal For Monthly Obesity Drug ↗

November 04, 2024

Ascendis Pharma and Novo Nordisk sign exclusive global license for TransCon technology, aiming to advance obesity, type 2 diabetes, and cardiovascular treatments.

Via Benzinga

If You Invested $100 In This Stock 15 Years Ago, You Would Have $5,600 Today ↗

November 04, 2024

Via Benzinga

Here's How Much You Would Have Made Owning Ascendis Pharma Stock In The Last 10 Years ↗

October 08, 2024

Via Benzinga

Looking Into Ascendis Pharma's Recent Short Interest ↗

September 26, 2024

Via Benzinga

Here's How Much You Would Have Made Owning Ascendis Pharma Stock In The Last 10 Years ↗

September 24, 2024

Via Benzinga

Earnings Scheduled For November 14, 2024 ↗

November 14, 2024

Via Benzinga

BioMarin's Pipeline Faces Skepticism As Analyst Questions Future Growth ↗

October 30, 2024

BioMarin posts Q3 EPS of $0.91, nearly doubling last year's $0.46 and topping estimates. Sales rose 28%, driven by strong Voxzogo growth. Analyst downgrades on lack of upcoming catalysts.

Via Benzinga

3 Oversold Stocks with Big RSI Rebound Potential

October 03, 2024

Everybody loves finding a bargain or getting a good deal, and it's no different when it comes to stocks. The RSI indicator is a great way to find them.

Via MarketBeat

Topics Economy

BioMarin Stands Firm on 2027 Revenue Target Amid Ascendis Competition, Goldman Sachs Analyst Remains Bullish ↗

September 25, 2024

BioMarin Pharmaceutical aims to achieve $4 billion in revenue by 2027, driven by Voxzogo adoption, despite emerging competition from Ascendis Pharma. Goldman Sachs maintains a "Buy" rating with a $139...

Via Benzinga

Bausch & Lomb And Edgewise Therapeutics Are Among Top 7 Mid Cap Stock Gainers Last Week (Sept 15-Sept 21): Are The Others In Your Portfolio? ↗

September 22, 2024

Federal Reserve's rate cut boosted tech, construction, industrial, machinery, and financial sectors. Top-performing mid-cap stocks last week.

Via Benzinga

Topics Economy

$100 Invested In This Stock 10 Years Ago Would Be Worth $5,900 Today ↗

August 09, 2024

Via Benzinga

Novo Nordisk, Chewy And FedEx Are Among Top 10 Large Cap Losers Last Week (Sept 15-Sept 21): Are The Others In Your Portfolio? ↗

September 22, 2024

10 large-cap stocks worst performers in last week: SMMT -23.61%, KSPI -21.66%, BMRN -16.74%, RIVN -13.26%, FDX -11.08%, BNTX -9.01%, AJG -7.17%, CHWY -6.97%, NVO -6.93%, MUSA -6.90%

Via Benzinga

Despite Being First Mover, BioMarin's Voxzogo For Dwarfism To Face Pressure From Ascendis' Candidate In Near Term ↗

September 16, 2024

BioMarin stock dips in response to TransCon CNP data, as analysts note TransCon CNP could challenge BioMarin's Voxzogo by late 2025 due to its dosing schedule and potential safety benefits.

Via Benzinga

Crude Oil Surges Over 1%; Instil Bio Shares Plunge ↗

September 16, 2024

Via Benzinga

Ascendis Pharma's Rare Dwarfism Candidate Shows Promise In Trial, FDA Submission Expected Next Year ↗

September 16, 2024

Ascendis Pharma reports positive topline data from the Phase 3 ApproaCH trial of TransCon CNP in children with achondroplasia.

Via Benzinga

Ascendis Rockets — And Hammers BioMarin — On New Results For Growth Drug ↗

September 16, 2024

The companies could soon face off in the growth treatment market for children with a genetic disorder.

Via Investor's Business Daily

Alcoa, Lattice Semiconductor, Stratasys And Other Big Stocks Moving Higher On Monday ↗

September 16, 2024

Via Benzinga

Ascendis Pharma Faces Challenges With Skytrofa And Yorvipath Pricing: Analysts Weigh In ↗

September 04, 2024

Ascendis Pharma reported disappointing Q2 sales of $38.76 million, missing the consensus of $92.7 million. Key updates included a higher-than-expected U.S. price for Yorvipath and a delayed cash flow...

Via Benzinga

Why Ascendis Pharma Stock Tumbled by 11% Today ↗

September 04, 2024

A bottom-line whiff and reduced guidance made the company an outlier for the wrong reasons on Hump Day.

Via The Motley Fool

Ascendis Pharma Slashes Its Outlook Amid Pricing Fiasco, Sacrifices A Breakout ↗

September 04, 2024

Shares are poised to undercut their 50-day and 200-day lines, and the lower boundary of a base.

Via Investor's Business Daily

Rare Disease-Focused Ascendis Pharma Stock Falls On Underwhelming Q2 Earnings, Guidance Cut ↗

September 04, 2024

Ascendis Pharma reported lower-than-expected Q2 2024 sales of $38.76 million, missing the consensus estimate of $92.7 million due to a significant adjustment to prior sales estimates. The company...

Via Benzinga

Core & Main Reports Downbeat Results, Joins Rev Group, PagerDuty, Dollar Tree And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session ↗

September 04, 2024

Via Benzinga

Royalty Pharma and Ascendis Pharma Enter Into $150 Million Royalty Funding Agreement

September 03, 2024

Proceeds to support continued development and commercialization of Endocrine Rare Disease products, including the Yorvipath U.S. commercial launch, and general corporate purposes

From Royalty Pharma plc

Via GlobeNewswire

Loar Holdings Posts Upbeat Results, Joins Nvidia, Clean Energy Fuels, Penumbra And Other Big Stocks Moving Higher On Tuesday ↗

August 13, 2024

Via Benzinga

Ascendis' Hypoparathyroidism Drug Scores FDA Approval As First and Only Treatment, Replacing Takeda's Drug Discontinued Due To Supply Issues ↗

August 12, 2024

FDA grants approval to Ascendis Pharma's Yorvipath (TransCon PTH) for adult hypoparathyroidism. Yorvipath offers continuous parathyroid hormone exposure and is set to launch in the U.S. with patient...

Via Benzinga

Ascendis Pharma Zips Higher After FDA Approves Embattled Thyroid Drug ↗

August 12, 2024

The company faced a number of regulatory setbacks that pushed its initial expected approval date out from April.

Via Investor's Business Daily

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.